The collapse of one potential mega-merger and the uncertain future of the other could hurt shoppers on the Affordable Care Act exchanges next year by leaving them with even fewer options and potentially higher prices.
A review by The Associated Press found Seema Verma and her small Indianapolis-based firm made millions through consulting agreements with at least nine states while also working under contract for Hewlett Packard.
Two local men who have been working on a potential blockbuster treatment for a rare and debilitating disease are hopeful that a major injection of venture capital will provide the boost needed to move the drug to market—even if it means sweeping changes for their company.
Anthem filed a notice of appeal on Thursday after a federal judge blocked its $48 billion deal to buy Cigna Corp.
Vice President Mike Pence may have just picked another fight with pharmaceutical companies—one that doesn’t involve drug prices.
While Anthem said it was “significantly disappointed” by the judge’s order and would seek an expedited appeal, Cigna said only that it “intends to carefully review the opinion and evaluate its options in accordance with the merger agreement.”
The deal, along with Aetna Inc.’s proposed tie-up with Humana Inc., which was blocked last month, was set to reduce the ranks of big U.S. health insurers to three from five and make Anthem the largest by membership.
The closure of an Indianapolis residential care facility is expected to result in the loss of 87 jobs, but some of the workers might be able to land employment at the same company.
The Trump administration and its pick to lead the Centers for Medicare & Medicaid Services are likely to champion the approach behind HIP 2.0—a Medicaid expansion that requires those receiving insurance coverage to have "skin in the game" by contributing financially.
The Indianapolis-based drugmaker has offered many of its research and development employees a compensation package if they leave the company.
For years, medical-device makers in Indiana and around the nation have insisted that the 2.3 percent tax on sales to help fund the Affordable Care Act has hurt business and slowed innovation.
Eli Lilly and Co. CEO Dave Ricks said he was encouraged by President Donald Trump’s understanding of the complexities of drug development, yet he’s concerned about risks the industry may face in a fresh overhaul of the U.S. health-care system.
The Affordable Care Act's insurance exchanges have become too risky for major health insurers, and that's creating further doubt about coverage options consumers might have next year.
For drugmakers, including Indianapolis-based Eli Lilly and Co., a meeting Tuesday with President Donald Trump was a dose of happy pills.
The NCAA and helmet maker Riddell are defendants in separate class-action lawsuits alleging they failed to protect football players from long-term head injuries and didn't educate them about the risks.
President Trump took Big Pharma to task on pricing but also promised to ease regulations and find ways to speed medicines to market, which triggered a surge in the sector’s share prices.
Indiana now has one of the lowest cigarette taxes in the nation. It also has one of the highest smoking rates. Some groups want to decrease the latter in part by raising the former.
Dr. Tristan Stonger is accused of operating a “pill mill” in Peru, where he saw as many as 100 patients in a single day. He also had offices in Bloomington and Indianapolis.
The number of transplants performed in Indiana last year hit an 11-year high, up about 6 percent from a year before, according to the Organ Procurement and Transplantation Network.
Planned Parenthood of Indiana and Kentucky Inc. is searching for a new president and CEO to succeed Betty Cockrum, who plans to retire in June.
